Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-50
SponsorSt. Jude Children's Research Hospital

About this trial

This pilot study will assess the usefulness and potential effectiveness of using transcutaneous auricular vagus nerve stimulation (tVNS) for treating insomnia in adult survivors of childhood acute lymphoblastic leukemia (ALL). Participants will be randomized to receive either active (verum) or inactive (sham) nightly stimulation using a non-invasive earbud device over two time periods: 2 weeks and 8 weeks. The study will assess adherence to the intervention and estimate its effects on sleep quality, stress, and neurocognitive function.

Primary Objective:

Aim 1: To determine a) short-term and b) long-term feasibility of tVNS in terms of participation in ALL Survivors with moderate to severe insomnia.

Aim 2: To estimate the effect size of tVNS on sleep quality, stress, and neurocognitive outcomes in ALL survivors with insomnia.

Exploratory Objectives

Aim 1: To investigate the onset of tVNS effect via actigraphy measures over the intervention epoch.

Aim 2: To estimate the effect size of genetic variants on sleep quality within verum tVNS.

Eligibility criteria

Qualifiers

Survivor of Acute Lymphoblastic Leukemia (ALL)

Enrolled on SJLIFE

Participant was less than 21 years of age at time of diagnosis.

Age 20-50 years at the time of enrollment

Disqualifiers

Unable to understand the details and requirements of the study (at the discretion of the PI)

Female participants who are pregnant or planning to become pregnant

Presence of implanted electrical medical devices (i.e. pacemaker)

Currently taking medication intended to treat neurocognitive impairment (i.e. stimulants) or medications prescribed for seizure management

Trial design

Treatments tested in this trial

  • Soterix tVNS device
  • Soterix tVNS device (sham programmed)
  • Sleep Quality
  • Neurocognitive and mental health outcomes

Treatment groups

40 Participants
are divided into 2 treatment groups